Quick Answer
Eloxx Pharmaceuticals, Inc. reported Operating Income of -$6.44 million for fiscal year 2025.
Eloxx Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$6.44M | -160.9% |
| 2024 | -$2.47M | +85.7% |
| 2023 | -$17.29M | +49.8% |
| 2022 | -$34.42M | +47.9% |
| 2021 | -$66.02M | -97.3% |
| 2020 | -$33.45M | +33.8% |
| 2019 | -$50.55M | -6.3% |
| 2018 | -$47.56M | -133.3% |
| 2017 | -$20.39M | -343.9% |
| 2017 | -$4.59M | +53.3% |
| 2016 | -$9.84M | +12.1% |
| 2016 | -$11.19M | -78.2% |
| 2015 | -$6.28M | +65.2% |
| 2015 | -$18.08M | -97.6% |
| 2014 | -$9.15M | -96.7% |
| 2013 | -$4.65M | +14.1% |
| 2012 | -$5.41M | +31.7% |
| 2011 | -$7.92M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | -$3.64M | +49.1% | +12.1% |
| June 30, 2023 | -$4.14M | +59.8% | +24.5% |
| March 31, 2023 | -$5.48M | +49.9% | +23.2% |
| September 30, 2022 | -$7.14M | +30.3% | +30.6% |
| June 30, 2022 | -$10.30M | +71.2% | +6.0% |
| March 31, 2022 | -$10.95M | -30.2% | -6.9% |
| September 30, 2021 | -$10.24M | -62.7% | +71.3% |
| June 30, 2021 | -$35.73M | -371.0% | -324.6% |
- Eloxx Pharmaceuticals, Inc. showed a decrease of -160.9% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Eloxx Pharmaceuticals, Inc.’s operating income has grown by 18.7% (from -$7.92 million to -$6.44 million).
- The most recent figure is from Eloxx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: